A combination of high body temperature, seizures, and SCN1A mutations can cause the rapid…
Ana Pena, PhD
Ana is a molecular biologist with a passion for discovery and communication. As a science writer, she looks for connecting the public, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Ana Pena, PhD
Two teenage girls with Dravet syndrome became seizure-free after starting contraceptive hormonal therapies containing synthetic estrogen and progesterone,…
Epidiolex, GW Pharmaceuticals’ investigational cannabis-based oral therapy, was proven safe in…
A database created at the University of Arizona College of Medicine — Phoenix…
Zogenix has completed enrolling patients in a second Phase 3 trial evaluating ZX008 as a treatment for Dravet syndrome epilepsy. Standard…
Sudden unexplained death in epilepsy (SUDEP) in patients with Dravet…